Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for non-alcoholic fatty liver disease
ChiCTR2300073720Phase 4Not yet recruiting
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Dapagliflozin group with Placebo group (2 arms). Primary endpoints: Liver-to-spleen attenuation ratio, Visceral fat area and 1 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2300073720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073720.